PamGene International B.V., an in-vitro diagnostics company focused on the development and commercialization of blood-based immunotherapy selection tests, today announced it has received extension of its ISO 13485:2016 certification. The extension completes PamGene’s ISO-certificate and is an important milestone in the company’s intensified focus on serving as a global service provider of immunotherapy selection with its IOpener® tests, and follows PamGene’s initial ISO certification in January 2019.